Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

Pancreatic Cancer: Addition of Eryaspase to Chemotherapy Versus Chemotherapy Alone

Research Question:
Does the the addition of eryaspase to chemotherapy improve patient health compared to chemotherapy alone?

Basic Study Information

Purpose:
The drug, Eryaspase, is made of L-asparaginase placed inside donor-derived red blood cells. It is designed to target the modified asparagine and glutamine metabolism of cancer cells. This is an open-label, multicenter, randomized, Phase 3 study in patients with ductal adenocarcinoma of the pancreas (pancreatic cancer) who have failed only one prior line of anti-cancer therapy.

Location: University of Rochester Medical Center
Study Reference #: IGIP19008

Lead Researcher (Principal Investigator)

Lead Researcher:  Aram Hezel

Study Contact Information

Study Coordinator: Chris LeFeber
Phone: (585) 275-0407
Email: Chris_LeFeber@URMC.Rochester.edu

Additional Study Details

Return to Search